Purdue Pharma LP operating subsidiary Imbrium Therapeutics LP announced the first dose administered in the Phase 2 clinical study (OAG2002) of its novel, potentially first-in-class small molecule IMB-115 for the treatment of insomnia associated with alcohol cessation. The randomized, double-blind, placebo-controlled, multi-center, parallel-group study evaluates the compound’s safety, efficacy, and tolerability in adults with moderate … Continue reading First Patient Dosed in Phase 2 Study of Potential Molecule for Insomnia Associated with Alcohol Cessation